ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

A QUASI-EXPERIMENTAL STUDY TO EXAMINE THE ACTION STATISTICS OF METFORMIN IN TYPE II DIABETES MELLITUS PATIENTS

M.Shamim ul Husnain, Sh. Sarmad Elahi, Zulqarnain Haider

Aim of Study: The main purpose of our study was to judge the action statistics of metformin in type II diabetes mellitus patients and in connection with this to examine the association of it with decrease of GIT and BMI. Study design: Quasi-Experimental study Place and duration: This study was carried out at Shaikh Zayed Hospital, Lahore for the time duration of one year starting from March, 2018 to February, 2019. Material and Methods: A total number of 200 patients, newly diagnosed of type II diabetes mellitus (T2DM) were included in this quasi experimental study. All selected patients were treated with dose of metformin for a time period of 03 months and after that they were divided into two groups known as Responder and Non-responder assessed by reductions of HbA1c (A1C). This was calculated via hemoglobin analyzer (TC4611A TAIDoc Tech. Taiwan) by means of photometry. Same alike, BMI on the first day and after 3 months of treatment was noted on a proforma. Results: All selected (200) patients of T2DM were treated with pre-decided dose of metformin for a time period of 03 months and after that they were divided into two groups known as Responder and Non-responder. There were 59.50% responder patients and 40.50% patients were non-responder. BMI at the start of the therapy was 26.09 kg/m2 which was considerably decreased to 25.4 kg/m2 after metformin treatment. Also observed that in all patients A1C was reduced due to metformin therapy. As compared to lower baseline levels of A1C as 0.61%±0.07, the glycemic control was significantly well in patients with higher baseline of A1C as 1.13% ± 0.08. While considering GIT intolerance, symptoms lacked in 140 patients amongst which there were 39.30% non-responders and rest 60.70% were responders. Conclusions: After treatment with metformin found improvement in 59.5% of newly diagnosed T2DM patients for glycemic control. Whereas, 40.50% patients didn’t improve which might be due to collective influences of various gene polymorphisms and their inter-action with non-genetic factors. Regardless of effects of metformin on HbA1C, it decreased the BMI of all selected patients. Furthermore, no difference found in both groups for the symptoms and signs of GIT. Keywords: Body Mass Index (BMI), GIT Intolerance, Type-II Diabetes Mellitus, Metformin, Glycemic Response.

FULL TEXT